인벤테라

0007J0KOSDAQ

52.8 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40

News Sentiment18.8 / 25

Momentum9.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 7.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Invenia is a biopharmaceutical company developing the 'Invinity™' polysaccharide-based nanotechnology platform to inhibit protein corona formation, enhance intrabody stability, and enable targeted drug delivery. The company focuses on addressing unmet medical needs through alternative MRI contrast agents and nano-medicines administered via oral or intra-articular injection methods.

Number of Employees

18people

Average Salary

78.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

4.63Industry Average 1.200.0Point

3.9x industry avg (risky)

ROE

-45.55Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

3.92Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 3.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

0.0 / 4

Detailed News Sentiment

3 totalPositive 2Neutral 0Negative 1Average Sentiment Score 75

Positive
인벤테라 "나노 MRI 조영제, 뇌 림프계 연구로 확장 가능성"
인벤테라는 나노 MRI 조영제의 뇌 림프계 연구 확장 가능성을 보여주는 긍정적인 비임상 결과 발표로 주가 상승 기대.
Negative
청약은 흥행, 주가는 뒷걸음…올해 상장 바이오텍들 반쪽짜리 ‘실탄...
Inventera's stock performance lags behind expectations despite successful IPOs, indicating investor skepticism.
Positive
살아나는 IPO 시장에…유진투자證, '7강 하우스' 목표 내걸었다
유진투자증권의 IPO 시장 회복 전망으로 인해 인벤테라와 관련된 투자 활동 증가 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 8,390Won52-week high 35,25052-week low 6,220

1-month return5.0Point

1m +7.02% (rising)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식매수선택권부여에관한신고2026-09-04
Neutral반기보고서 (2026.06)2026-08-14